EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Disease Progression in Charcot‐Marie‐Tooth Disease Type 4B ( CMT4B ) Associated With Mutations in Myotubularin‐Related Proteins 2 and 13

Alessandro Bertini, Mary M Reilly, Chiara Pisciotta iD, Stefano C Previtali iD, Yesim Parman, Esra Battaloglu, Matilde Laurà, Julian Blake, Sabrina Sacconi, Shahram Attarian, Tanya Stojkovic, Mounia Bellatache und 21 weitere

European Journal of Neurology · 2025

DOI: 10.1111/ene.70084 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Alessandro Bertini und 32 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Rare Neurological Diseases, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease, Disease Progression, Protein Tyrosine Phosphatases, Non-Receptor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NINDS NIH HHS, Italian Ministry of Health (RRC), Charcot-Marie-Tooth Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims In 2019, we conducted a cross‐sectional study, collecting information on 50 patients with CMT4B, an ultrarare CMT subtype, to better define the clinical phenotype. We now aimed at investigating disease progression in 26 patients with CMT4B1/CMT4B2, recruited from the previous study and among the Inherited Neuropathy Consortium. Materials and Methods We retrospectively analysed disease progression in patients with CMT4B1/CMT4B2, collecting MRC scores from nine muscle pairs, Charcot‐Marie‐Tooth Examination Score (CMTES), and a minimal dataset of clinical information (walking difficulties, aids dependency, upper limb impairment, cranial nerves involvement) at baseline and follow‐up visits. Thirteen centres from four continents were involved.

Results

Thirteen CMT4B1 and 13 CMT4B2 patients were followed up for 7.1 ± 4.9 and 7.9 ± 4.5 years, respectively. During follow‐up, walking aid dependency increased: two CMT4B1 patients adopted AFOs (overall 11/12 at follow‐up), and one started using wheelchair (6/12 at follow‐up) at the age of 19; among CMT4B2 patients, two more required unilateral support in walking (4/11 at follow‐up) by the age of 33 and 49 years, respectively. We found that disease progression, as measured by CMTES, was faster in CMT4B1 as compared to CMT4B2 patients (ΔCMTES/year 0.7 vs. 0.3, p = 0.037) but tended to slow down over time as burden of disease increased. At the end of follow‐up, CMT4B1 was associated to higher disability.

Conclusions

This international collective effort enabled collection of relevant data for characterizing natural history and estimating disease progression of CMT4B1/CMT4B2 ultrarare diseases, aiming at improving their management and paving the way for designing future clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Charcot-Marie-Tooth DiseaseDisease ProgressionProtein Tyrosine Phosphatases, Non-ReceptorHumansMaleFemaleAdultMiddle AgedCross-Sectional StudiesRetrospective StudiesMutationYoung AdultAdolescent

Stichwörter der Autor:innen

CMT4BCharcot‐Marie‐Tooth diseaseneuromuscular

Substanzen

Protein Tyrosine Phosphatases, Non-Receptor

Autor:innen und Institutionen

  • Unit of Rare Neurological Diseases, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, England.
  • Institute of Experimental Neurology (InSpe), Division of Neuroscience, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Neurology Unit, IRCCS Ospedale San Raffaele, Milan, Italy.
  • Neuromuscular Unit, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.
  • Bogazici University, Department of Molecular Biology and Genetics, Istanbul, Turkey.

ORCID-Profile: Chiara Pisciotta, Stefano C Previtali, Antonio Gambardella, Rita Horvath, Mario Sabatelli, Marco Luigetti, Stefano Tozza, Fiore Manganelli, Alessandra Bolino, Davide Pareyson

Förderung

  • NINDS NIH HHS
  • Italian Ministry of Health (RRC)
  • Charcot-Marie-Tooth Association
  • Ministero della Salute

Zitieren

APA

Bertini, A., Reilly, M. M., Pisciotta, C., Previtali, S. C., Parman, Y., Battaloglu, E., Laurà, M., Blake, J., Sacconi, S., Attarian, S., Stojkovic, T., Bellatache, M., Nouioua, S., Tazir, M., Cakar, A., Gambardella, A., Valentino, P., Lewis, R. A., Horvath, R., …, & Inherited Neuropathy Consortium (2025). Disease Progression in Charcot‐Marie‐Tooth Disease Type 4B ( CMT4B ) Associated With Mutations in Myotubularin‐Related Proteins 2 and 13. European Journal of Neurology. https://doi.org/10.1111/ene.70084

Vancouver

Bertini A, Reilly MM, Pisciotta C, Previtali SC, Parman Y, Battaloglu E, et al. Disease Progression in Charcot‐Marie‐Tooth Disease Type 4B ( CMT4B ) Associated With Mutations in Myotubularin‐Related Proteins 2 and 13. European Journal of Neurology. 2025. doi:10.1111/ene.70084

BibTeX
@article{Bertini2025,
  author = {Bertini, Alessandro and Reilly, Mary M and Pisciotta, Chiara and Previtali, Stefano C and Parman, Yesim and Battaloglu, Esra and Laurà, Matilde and Blake, Julian and Sacconi, Sabrina and Attarian, Shahram and Stojkovic, Tanya and Bellatache, Mounia and Nouioua, Sonia and Tazir, Meriem and Cakar, Arman and Gambardella, Antonio and Valentino, Paola and Lewis, Richard A and Horvath, Rita and Zambon, Alberto A and Sabatelli, Mario and Luigetti, Marco and Tozza, Stefano and Manganelli, Fiore and Herrmann, David N and Scherer, Steven S and Kressin, Nicole and Ward, Kailee and Bolino, Alessandra and Shy, Michael E and Pareyson, Davide and CMT4B Study Group, CMT4B Study Group and Inherited Neuropathy Consortium, Inherited Neuropathy Consortium},
  title = {Disease Progression in Charcot‐Marie‐Tooth Disease Type 4B ( CMT4B ) Associated With Mutations in Myotubularin‐Related Proteins 2 and 13},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70084}
}
Kostenlos starten →